{
    "Orphapacket": {
        "ORPHApacketId": "83467",
        "creationDate": "2025-06-26 11:48:15",
        "version": "1.3.42 / 4.1.8 [2025-03-03]",
        "copyright": "Orphanet (c) 2025",
        "ORPHAcode": "83467",
        "Label": "Morvan syndrome",
        "PURL": "http://www.orpha.net/ORDO/Orphanet_83467",
        "DisorderType": {
            "value": "Disease",
            "PURL": "http://www.orpha.net/ORDO/Orphanet_377788"
        },
        "Synonyms": [
            {
                "Synonym": "Limbic encephalitis-neuromyotonia-hyperhidrosis-polyneuropathy syndrome"
            },
            {
                "Synonym": "Morvan fibrillary chorea"
            }
        ],
        "TextSection": {
            "TextSectionType": "Definition",
            "Contents": "Morvan syndrome is a rare life-threatening acquired neurologic disease characterized by neuromyotonia dysautonomia and encephalopathy with severe insomnia. Signs involving central (e.g. hallucinations confusion amnesia myoclonus) autonomic (e.g. variations in blood pressure hyperhidrosis) and peripheral (e.g. painful cramps myokymia) hyperactivity as well as systemic manifestations (such as weight loss pruritus fever) are reported. Thymoma is present in some cases."
        },
        "Parents": [
            {
                "Parent": [
                    {
                        "ORPHAcode": "98750",
                        "Label": "Autoimmune neurological channelopathy"
                    }
                ]
            },
            {
                "Parent": [
                    {
                        "ORPHAcode": "166484",
                        "Label": "Inflammatory and autoimmune disease with epilepsy"
                    }
                ]
            },
            {
                "Parent": [
                    {
                        "ORPHAcode": "221114",
                        "Label": "Acquired peripheral movement disorder"
                    }
                ]
            }
        ],
        "Phenotypes": [
            {
                "Phenotype": {
                    "HPOId": "HP:5000005",
                    "HPOTerm": "Anti-CASPR2",
                    "HPOFrequency": "Frequent (79-30%)"
                }
            }
        ],
        "Prevalences": [
            {
                "Prevalence": {
                    "Source": "27698847[PMID]",
                    "PrevalenceType": "Cases/families",
                    "PrevalenceQualification": "Case(s)",
                    "PrevalenceClass": "no data",
                    "ValMoy": "no data",
                    "PrevalenceGeographic": "Worldwide"
                }
            },
            {
                "Prevalence": {
                    "Source": "ORPHANET_27698847[PMID]",
                    "PrevalenceType": "Point prevalence",
                    "PrevalenceQualification": "Class only",
                    "PrevalenceClass": "<1 / 1 000 000",
                    "ValMoy": "no data",
                    "PrevalenceGeographic": "Worldwide"
                }
            }
        ],
        "AverageAgeOfOnsets": {
            "AverageAgeOfOnset": [
                {
                    "value": "Adult"
                }
            ]
        }
    }
}